Overview

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Status:
Not yet recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.

Phase:

Phase 1

Details

Lead Sponsor:

Sciwind Biosciences APAC CO Pty. Ltd.

Collaborator:

Hangzhou Sciwind Biosciences Co., Ltd.